NASDAQ:DMTKDermTech Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding DermTech Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $10.79 -0.21 (-1.91 %) (As of 04/5/2020 04:00 PM ET) Add Compare Share Today's Range$10.67Now: $10.79▼$11.0050-Day Range$8.98MA: $12.51▼$15.9852-Week Range$4.52Now: $10.79▼$23.24Volume11,892 shsAverage Volume60,317 shsMarket Capitalization$160.12 millionP/E RatioN/ADividend YieldN/ABeta0.74 ProfileAnalyst RatingsAdvanced ChartEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media DermTech, Inc., a molecular genomics company, develops and markets novel non-invasive diagnostic tests to diagnosis skin cancer and related conditions in the United States. The company offers Pigmented Lesion Assay (PLA), a gene expression test that helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. It also provides Nevome test, an adjunctive reflex test for the PLA; and adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. The company sells its products to pathology and oncology practitioners. DermTech, Inc. was incorporated in 1995 and is headquartered in La Jolla, California.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingDermTech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $24.00, DermTech has a potential upside of 122.4% from its current price of $10.79.Amount of Analyst CoverageDermTech has only been the subject of 1 research reports in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesDermTech has received 13 “outperform” votes. (Add your “outperform” vote.)Underperform VotesDermTech has received 11 “underperform” votes. (Add your “underperform” vote.)Community SentimentDermTech has received 54.17% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about DermTech and other stocks. Vote “Outperform” if you believe DMTK will outperform the S&P 500 over the long term. Vote “Underperform” if you believe DMTK will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldDermTech does not currently pay a dividend.Dividend GrowthDermTech does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, DermTech insiders have bought more of their company's stock than they have sold. Specifically, they have bought $3,410,416.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 21.00% of the stock of DermTech is held by insiders.Percentage Held by InstitutionsOnly 24.93% of the stock of DermTech is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Book Value per Share RatioDermTech has a P/B Ratio of 10.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.84 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DMTK Previous Symbol CUSIPN/A CIKN/A Webhttp://www.dermtech.com/ Phone858-450-4222Debt Debt-to-Equity RatioN/A Current Ratio3.00 Quick Ratio2.99Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$3.36 million Price / Sales47.66 Cash FlowN/A Price / Cash FlowN/A Book Value$1.01 per share Price / Book10.68Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-19,690,000.00 Net MarginsN/A Return on Equity-81.72% Return on Assets-52.28%Miscellaneous Employees36 Outstanding Shares14,840,000Market Cap$160.12 million Next Earnings DateN/A OptionableNot Optionable Receive DMTK News and Ratings via Email Sign-up to receive the latest news and ratings for DMTK and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:DMTK Rates by TradingView DermTech (NASDAQ:DMTK) Frequently Asked Questions How has DermTech's stock been impacted by COVID-19 (Coronavirus)? DermTech's stock was trading at $14.37 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, DMTK shares have decreased by 24.9% and is now trading at $10.79. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of DermTech? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DermTech in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for DermTech. What price target have analysts set for DMTK? 1 equities research analysts have issued 12 month target prices for DermTech's shares. Their forecasts range from $24.00 to $24.00. On average, they expect DermTech's stock price to reach $24.00 in the next twelve months. This suggests a possible upside of 122.4% from the stock's current price. View analysts' price targets for DermTech. Has DermTech been receiving favorable news coverage? News articles about DMTK stock have been trending very negative on Sunday, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. DermTech earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutDermTech. Who are some of DermTech's key competitors? Some companies that are related to DermTech include Castle Biosciences (CSTL), RadNet (RDNT), Centogene (CNTG), Personalis (PSNL), Fulgent Genetics (FLGT), Enzo Biochem (ENZ), Anpac Bio-Medical Science (ANPC), Celcuity (CELC), Psychemedics (PMD), Biocept (BIOC), Miragen Therapeutics (MGEN), OpGen (OPGN), Avant Diagnostics (AVDX), CBA Florida (CBAI) and PotNetwork (POTN). What other stocks do shareholders of DermTech own? Based on aggregate information from My MarketBeat watchlists, some companies that other DermTech investors own include AT&T (T), NovaBay Pharmaceuticals (NBY), Gilead Sciences (GILD), AbbVie (ABBV), Carnival (CCL), Southern (SO), Exxon Mobil (XOM), Crispr Therapeutics (CRSP), Huntington Bancshares (HBAN) and JD.Com (JD). Who are DermTech's key executives? DermTech's management team includes the following people: Dr. John D. Dobak, Pres, CEO & Director (Age 53)Mr. Kevin Sun, CFO, Treasurer & Sec.Ms. Claudia Ibarra, Chief Operating Officer (Age 57)Dr. Zuxu Yao, Chief Scientific Officer (Age 57)Ms. Sarah Dennison, VP of Marketing What is DermTech's stock symbol? DermTech trades on the NASDAQ under the ticker symbol "DMTK." How do I buy shares of DermTech? Shares of DMTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is DermTech's stock price today? One share of DMTK stock can currently be purchased for approximately $10.79. How big of a company is DermTech? DermTech has a market capitalization of $160.12 million and generates $3.36 million in revenue each year. DermTech employs 36 workers across the globe. View additional information about DermTech. What is DermTech's official website? The official website for DermTech is http://www.dermtech.com/. How can I contact DermTech? DermTech's mailing address is 11099 N. Torrey Pines Road Suite 100, La Jolla CA, 92037. The company can be reached via phone at 858-450-4222 or via email at [email protected] This page was last updated on 4/5/2020 by MarketBeat.com StaffFeatured Article: Marijuana Stocks Investing Considerations
